ASH 2023: Multiple Myeloma's Shifting Landscape: Trials and Clinical Perspectives

EP: 1.Unmet Needs In Multiple Myeloma Management

EP: 2.Evolving Goals in Multiple Myeloma Treatment

EP: 3.Multiple Myeloma Induction Challenges and Future Options

EP: 4.Optimizing Multiple Myeloma Treatment: Quadruplet Therapy

EP: 5.Real-World Insights: Multiple Myeloma Treatment Challenges

EP: 6.Navigating the Multiple Myeloma Treatment Landscape

EP: 7.Real-world Multiple Myeloma Treatment: Insights and Challenges

EP: 8.The Future of Multiple Myeloma Treatment

Now Viewing

EP: 9.ASH 2023: Multiple Myeloma's Shifting Landscape: Trials and Clinical Perspectives

EP: 10.Multiple Myeloma Frontline Horizon: Quads, Bispecifics, and Breakthroughs

This is a video synopsis/summary of a Peer Exchange featuring Joshua Richter, MD; Rafat Abonour, MD; Faith Davies, MD; and Amrita Krishnan, MD.

In a discussion about anticipated abstracts at ASH 2023, Krishnan expresses excitement about the PERSEUS trial (NCT03710603), emphasizing its potential practice-changing impact. Abonour highlights the significance of late-breaking abstracts, especially those focusing on combination therapies, monitoring using circulating DNA, and minimally invasive approaches. Davies is enthusiastic about translational studies, particularly single-cell sequencing, aiming to understand patient responses and nonresponses to immune therapies. Richter mentions a clinical trial that is a follow-up from a determination trial, suggesting potential differences in outcomes for African American patients with higher body mass index, sparking debate among the panel about its implications and the need for further investigation.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.